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Implantation of an embryo induces rapid proliferation and differentiation of uterine stromal cells,
forming a new structure, the decidua. One salient feature of decidua formation is a marked
increase in maternal angiogenesis. Vascular endothelial growth factor (VEGF)-dependent path-
ways are active in the ovary, uterus, and embryo, and inactivation of VEGF function in any of these
structures might prevent normal pregnancy development. We hypothesized that decidual angio-
genesis is regulated by VEGF acting through specific VEGF receptors (VEGFRs). To test this hypoth-
esis, we developed a murine pregnancy model in which systemic administration of a receptor-
blocking antibody would act specifically on uterine angiogenesis and not on ovarian or embryonic
angiogenesis. In our model, ovarian function was replaced with exogenous progesterone, and
blocking antibodies were administered prior to embryonic expression of VEGFRs. After adminis-
tration of a single dose of the anti-VEGFR-2 antibody during the peri-implantation period, no
embryos were detected on embryonic d 10.5. The pregnancy was disrupted because of a significant
reduction in decidual angiogenesis, which under physiological conditions peaks on embryonic d 5.5
and 6.5. Inactivation of VEGFR-3 reduced angiogenesis in the primary decidual zone, whereas
administration of VEGFR-1 blocking antibodies had no effect. Pregnancy was not disrupted after
administration of anti-VEGFR-3 or anti-VEGFR-1 antibodies. Thus, the VEGF/VEGFR-2 pathway
plays a key role in the maintenance of early pregnancy through its regulation of peri-implantation
angiogenesis in the uterine decidua. This newly formed decidual vasculature serves as the first
exchange apparatus for the developing embryo until the placenta becomes functionally active.
(Endocrinology 150: 3845–3854, 2009)
Formation of the uterine decidua during implantation sharesmany features of corpus luteum formation. Uterine decidu-
alization is characterized by rapid proliferation and differentia-
tion of resident stromal fibroblasts into large epithelioid-like
decidual cells (1, 2). Endothelial cells (EC) in close proximity to
decidual cells proliferate to form a new dense vascular network
in the pregnant uterus (3–5). Similarly, granulosa cell prolifer-
ation, differentiation into luteinized cells, and angiogenesis, the
formation of vasculature from preexisting vessels, are required
for corpora luteum formation and function (6, 7). In situ hy-
bridization demonstrates that signaling components of the
VEGF/VEGFR-2 pathway are expressed in the decidua during
the early postimplantation period (3), and functional studies in-
dicate that VEGF might be involved in the regulation of uterine
angiogenesis and implantation in the rodent (8–11) and nonhu-
man primate (12). VEGF and VEGFR-2 are also expressed dur-
ing corpus luteum formation in the rodent, nonhuman primate,
and human (13, 14). Functional studies using inhibitors of an-
giogenesis like anti-VEGF antibodies, VEGF Trap (15), or
VEGFR-2 blocking antibodies (6, 16) demonstrate that the
VEGF/VEGFR-2 signaling pathway plays a key role in the reg-
ulation of angiogenesis in corpora lutea (7, 14, 17).
Decidual angiogenesis and maintenance of vasculature in the
early postimplantation period is an absolute requirement for
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normal pregnancy development. It is thought that the newly
formed decidual vasculature serves as the first exchange appa-
ratus for the developing embryo until the placenta becomes func-
tionally competent (18). Given the aforementioned similarities
between uterine deciduae and corpora lutea, we hypothesized
that a key regulator of decidual angiogenesis is the VEGF/
VEGFR-2 pathway. To test this hypothesis, we inhibited
VEGFR-2 function with DC101, the VEGFR-2 neutralizing an-
tibody that has been successfully used to elucidate the regulation
of ovarian angiogenesis (6, 14, 16, 19). Because VEGFR-1 and
VEGFR-3 are also expressed in uterine deciduae (3, 20, 21) and
are involved in the regulation of vessel formation (22–24), we
used specific blocking antibodies to determine whether these
receptors have a functional role in the regulation of peri-implan-
tation uterine angiogenesis.
We report that a single peri-implantation injection of an anti-
VEGFR-2 blocking antibody disrupts pregnancy development
through reduction of angiogenesis in the uterine decidua. Ad-
ministration of an anti-VEGFR-3 blocking antibody reduces
peri-implantation uterine angiogenesis without precluding




The experiments were designed to investigate whether VEGF recep-
tors (VEGFRs) play an important role in the formation and function of
uterine decidual blood vessels during early pregnancy development. Sev-
en-to eight-week old female CD1 mice (Charles River Laboratories In-
ternational, Inc., Wilmington, MA) were mated with adult males from
1700–2300 h. Identification of a vaginal plug the following morning was
interpreted as successful mating. 1100 h was considered d 0.5 post co-
itum. On embryonic d (ED) 3.5  2 h, four extended-release progester-
one (P4) capsules (10 mg P4 per capsule, 21-d release, 4-mm diameter;
Innovative Research of America, Sarasota, FL) were placed under the
skin of pregnant mice. A bilateral ovariectomy was performed 4 h after
placement of the P4 capsules (16) (Fig. 1A). In intact pregnancies, average
P4 levels were 29.3 ng/ml and greater than 40 ng/ml on ED 6.5 and 10.5,
respectively. P4-replaced, ovariectomized, pregnant mice (PROPmice)
with P4 levels greater than 30 ng/ml at the time of death, which made up
95% of the animals, were used for all experiments. For each experiment,
a single ip injection of 0.5 ml neutralizing antibodies against either
VEGFR-2 (DC101) (14), VEGFR-3 (mF4-31C1) (25), VEGFR-1 (MF-1)
(22), or saline was administered on ED 3.75 (Fig. 1A). These neutralizing
antibodies, provided by ImClone Systems, Inc. (New York, NY), have
been used to inhibit signaling from VEGFRs in murine models of tumor
angiogenesis, lymphangiogenesis, atherosclerosis, and ovarian follicu-
logenesis (23–29). The dosages of VEGFR-neutralizing antibodies were
as follows: DC101 (66 mg/kg), mF4-31C1 (132 mg/kg), and MF-1 (132
mg/kg). All protocols were approved by the Institutional Animal Care
and Use Committee of Columbia University.
Dosage and behavior of DC101, mF4-31C1 and MF-1 in
vivo
Similar to previous studies, no adverse systemic effects were detected
after ip administration of rat antimouse antibodies against VEGFR-2
(DC101) (16, 26), VEGFR-3 (mF4-31C1) (25), or VEGFR-1 (MF-1) (22,
27). Dose-response curves using DC101, mF4-31C1, and MF-1 were
performed by injecting a single dose (33, 66, 132, or 264 mg/kg) of each
antibody on ED 3.75 and evaluating the effects on uterine angiogenesis
on ED 7.5. For DC101, angiogenesis was inhibited at 66 mg/kg. This
inhibition did not increase in magnitude with higher dosages of DC101.
Therefore, a dosage of 66 mg/kg, which is sufficient to inhibit ovarian
angiogenesis (19), was chosen for our experiments. For mF4-31C1, an
inhibitory response was seen at 132 mg/kg. This did not increase in
magnitude with higher dosages. Thus, 132 mg/kg was chosen for our
experiments. For MF-1, no significant inhibitory response was seen up
to 264 mg/kg. For our experiments, we selected an amount of 132 mg/kg,
which is four times the dosage of MF-1 used to inhibit angiogenesis in a
tumor model (30).
Similar to previous studies, injection of isotype-matched IgG and
saline produced identical results (n  5), but nonspecific IgG increased
background staining in immunohistochemistry (16, 19). Saline was used
for all controls.
Blocking antibodies against VEGFRs could penetrate the embryo and
disrupt early embryonic development because these receptors are ex-
pressed in early pregnancy (31), and homozygous null mutations in
VEGFR-1, -2, and -3 are embryonic lethal (32–35). To test whether
VEGFR-blocking antibodies bind to VEGFRs in the embryo, PROPmice
received ip injections of either DC101, mF4-31C1, or MF-1 on ED 9.5
and were killed on ED 10.5. Cross-sections of ED 10.5 uteri were in-
cubated with rabbit antirat biotinylated secondary antibody (1:100).
Specific binding was detected in the uteri but not in the embryos. As a
positive control, uterine cross-sections from untreated ED 10.5 mice
were incubated with either DC101, mF4-31C1, or MF-1 (all 1:50) fol-
lowed by the secondary antibody. Binding was detected in the uteri and
embryos. As a negative control, ED 10.5 uteri from mice treated with rat
IgG were incubated with the secondary antibody. No binding was de-
tected in the uteri or embryos. These experiments demonstrated that our
blocking antibodies can bind VEGFRs in both the uterus and embryo, but
maternal systemic administration does not result in binding to embryos.
Formation of the decidua
Control mice received ip injections of saline on ED 3.75, whereas
treatment group animals received either DC101, mF4-31C1, MF-1, or
combined DC101/mF4-31C1. The animals were killed on ED 5.5 to
FIG. 1. PROPmice have normal pregnancy development on ED 10.5. A,
Experimental design for P4 replaced-ovariectomized pregnant mice (PROPmice).
B, Mean uterine weights, numbers of embryos, and P4 levels in the intact mice
and PROPmice were similar on ED 10.5 (n  5 per group; P  0.05 by Student’s
t test). The appearance of ED 10.5 embryos from intact mice (C) was
indistinguishable from that of embryos from PROPmice (D).
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assess cellular proliferation and on ED 7.5 to evaluate the number of
implantation sites, decidual blood vessel density, cellular proliferation,
and apoptosis. To assess stromal cell differentiation by alkaline phos-
phatase staining, ED 6.5 uteri were fixed in 4% paraformaldehyde for 2 h
followed by a sucrose gradient. Frozen sections cut at 5 m were post-
fixed with 0.2% glutaraldehyde, rinsed in Tris buffer, treated for 10–20
min with 4.5 l/ml nitro blue tetrazolium chloride (33 mg/ml in dimethyl-
formamide; Sigma- Aldrich, St. Louis, MO), 3.5 l/ml 5-bromo-4-chloro-
3-indolylphosphate (50mg/ml indimethylformamide;Sigma),100mMTris
(pH 9.5), 100 mM NaCl, 50 mM MgCl2, and 0.1% Triton X-100, and
counterstained with Nuclear Fast Red (GeneTex, Irvine, CA).
Embryonic development
Peri-implantation
To evaluate whether direct actions of antibodies on uterine deciduae
have secondary, indirect effects on embryonic development, saline,
DC101, mF4-31C1, or MF-1 were administered to each sample on ED
3.75 and pregnancy was assessed on ED 10.5. The number of implan-
tation sites and embryos and the average embryo weight were deter-
mined. Uterine cross-sections were processed to evaluate embryo mor-
phology in each group.
Postimplantation
To test whether these antibodies could directly affect embryonic de-
velopment, we injected the embryos with VEGFR-blocking antibodies
on ED 6.5, a point when embryos start to express VEGFRs and formation
of deciduae is almost complete. Control mice received ip injections of
saline and treatment group animals each received either DC101, mF4-
31C1, or MF-1 on ED 6.5. The animals were killed on ED 10.5, and uteri
were processed as described below.
Artificial decidualization
Female CD1 mice were mated with vasectomized males. On d 3.5 of
pseudopregnancy, placement of P4 capsules and bilateral ovariectomy
were performed as described above. At the time of ovariectomy, one
uterine horn was infused with 10 l of sesame oil (Sigma) to induce
artificial decidualization. The noninfused uterine horn served as a con-
trol. Animals were randomized into two groups. Controls received ip
injections of saline and treatment group animals received the DC101/
mF4-31C1 combination. Uteri were removed on d 6.5 of pseudopreg-
nancy, and processed for immunohistochemical evaluation of EC.
Histology, immunohistochemistry, and
immunofluorescence
Frozen uteri containing embryos were sliced into 5-m sections at
50-m intervals and mounted on glass slides. Hematoxylin and eosin
(H&E) staining and immunohistochemistry were performed according
to standard procedures (19). The following primary antibodies were used
for immunohistochemistry: 1) platelet endothelial cell adhesion molecule
(PECAM; biotinylated rat antimouse CD31 antibody; 1:500; BD Pharm-
ingen, San Diego, CA), 2) goat antimouse VEGFR-2 antibody (1:250;
R&D Systems, Inc., Minneapolis, MN), 3) goat antimouse VEGFR-1
(1:200; R&D Systems, Inc.), and 4) goat antimouse VEGFR-3 (1:100;
R&D Systems, Inc.). Incubation with biotinylated secondary antibodies
(Vector Laboratories, Burlingame, CA) was followed by incubation with
avidin and horseradish peroxidase-conjugated biotin (Vectastain Stan-
dard ABC Elite kit; Vector). The color reaction was performed with
diaminobenzidine tetrahydrocholoride.
To study coexpression using immunofluorescence staining, the fol-
lowing combinations were used: 1) biotinylated rat antimouse CD31
(1:500; BD Pharmingen) in combination with VEGFR-1, -2, or -3 as
described above; 2) coexpression of VEGFR-1/VEGFR-2: rat antimouse
MF-1 (1:50; ImClone) with goat antimouse VEGFR-2 (1:250; R&D); 3)
coexpression of VEGFR-2/VEGFR-3: goat antimouse VEGFR-2 (1:250;
R&D) with rat antimouse VEGFR-3 (1:50; eBioscience, San Diego, CA);
and 4) coexpression of VEGFR-1/VEGFR-3: goat antimouse VEGFR-1
(1:200; R&D) with rat antimouse VEGFR-3 (1:50; eBioscience). Sec-
tions were incubated with secondary antibodies and signals were visu-
alized with fluorescent dye conjugates of streptavidin: AlexaFluor488
and AlexaFluor594 (Molecular Probes, Eugene, OR). After staining for
one receptor, avidin-biotin-blocking solution (Vector) was used to pre-
vent nonspecific staining while detecting expression of the second re-
ceptor. Images were photographed with an Axioscope 2 plus microscope
camera (Zeiss, Göttingen, Germany) and Axiocam HRC digital (Zeiss).
Double images were created with Adobe Photoshop Version 6.0 (Adobe
Systems, Inc., San Jose, CA).
Cellular proliferation and apoptosis
One hour before they were killed, animals were injected with 5-bro-
mo-2-deoxyuridine (BrDU; 1 ml/100 g animal weight; Zymed Labora-
tories, Inc., San Francisco, CA). Proliferating cells were identified with a
biotinylated BrDU antimouse primary antibody (Zymed kit). To detect
proliferating EC, double staining for BrDU and PECAM was used (19).
Apoptotic cells were detected using ApopTag Peroxidase In Situ Apo-
ptosis Detection Kit (Chemicon International, Temecula, CA).
RT-PCR
Decidual tissue isolated from the embryo, extraembryonic structures,
and myometrium was obtained from implantation sites on ED 6.5. Three
hundred nanograms of total RNA extracted using TRIzol (Invitrogen,
Carlsbad, CA) and treated with DNase I (Invitrogen) were reverse-tran-
scribed using the SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen). Primers to amplify VEGFA, VEGFC, and VEGFD were
designed. Standard PCR with 25 amplification cycles was performed.
PCR products were sequenced to confirm identity.
Serum P4
Blood was obtained from all animals by cardiopuncture immediately
before they were killed. Serum P4 levels were measured using a compet-
itive chemiluminescent immunoassay (Diagnostic Products Corp./Sie-
mens, Los Angeles, CA).
Data analysis
Quantitative analysis of EC, stromal cells, cellular proliferation, and
apoptosis was performed using an image analysis system linked to an
Axioscope 2 plus microscope. The data were processed with AxioVision
software version 4.5 (Zeiss). On ED 7.5, the area of decidua in a uterine
cross-section was measured (in square millimeters). The percentage of
the decidua occupied by blood vessels was calculated by dividing the total
area of PECAM staining by the area of decidua multiplied by 100. The
intense ring of PECAM staining around the embryo, the embryo, and the
peripheral muscularis layer were excluded.
To assess proliferation, the decidua of a uterine cross-section was
outlined. The image analysis system was configured to measure the num-
ber of brown-stained nuclei (i.e. BrDU-positive cells) using the segmen-
tation part of the program. An adjacent section, stained with hematox-
ylin, was used to count the total number of the cells. Proliferation indices
were calculated on ED 5.5 and 7.5 by dividing the number of BrDU-
positive cells by the total number of cells multiplied by 100. This strategy
was used to quantify apoptosis and stromal cell differentiation.
Statistics
Statistical analyses were performed using the Statistical Package for
Social Science version 15.0 (SPSS, Inc., Chicago, IL). Data are presented
as mean  SE. Unpaired Student’s t test and ANOVA with Bonferroni
correction were used to compare sample means. P  0.05 was considered
a statistically significant difference.
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Results
Normal embryonic development is maintained after P4
replacement and bilateral ovariectomy
PROPmice were used to evaluate the effect of blocking
VEGFR-1, -2, and -3 on uterine function during the peri-im-
plantation period. To demonstrate that pregnancy progresses
normally in this experimental model, PROPmice and intact preg-
nant controls received a single ip injection of saline on ED 3.75.
On ED 10.5, there were no differences in uterine weights, num-
bers of embryos, gross embryo morphology, or maternal serum
P4 levels between PROPmice and intact controls (Fig. 1).
Patterns of angiogenesis, cellular proliferation, and
stromal cell differentiation are maintained in PROPmice
Blood endothelial cells (BEC) expressing PECAM are prom-
inent throughout the endometrium and myometrium of the
uterus on ED 3.5 before ovariectomy. After
implantation, vascular density increases
with the peak decidual vascular density be-
tween ED 6.5 and 7.5 (Fig. 2Q). Subse-
quently, vascular density declines with re-
duction most pronounced at sites of placenta
formation (Fig. 2, A–E).
Intense staining for PECAM was noted in
the uterine decidua directly surrounding the
embryo on ED 5.5 and 6.5 (Fig. 2, B and C).
This PECAM staining was observed in intact
mice (supplemental Fig. 1, published as sup-
plemental data on The Endocrine Society’s
Journals Online web site at http://endo.
endojournals.org) and has been noted by
others (36). It does not show a vascular pat-
tern or expression of VEGFRs, markers of
EC. Thus, this PECAM staining does not re-
flect typical blood vessels. Some of the stain-
ing for PECAM might be due to the presence
of leukocytes and/or apoptotic cells (supple-
mental Fig. 2).
Cellular proliferation in the decidua
peaks on ED 5.5 (Fig. 2Q). The amount of
cellular proliferation declines more than
50% on ED 6.5. On ED 8.5, there are few
BrDU-positive cells in the decidua. The re-
maining proliferating cells are located at sites
of placenta formation (Fig. 2, F–J). Whereas
cellular proliferation occurs throughout the
decidua, including the primary decidual
zone (PDZ), on ED 5.5, cellular prolifera-
tion is restricted to the secondary decidual
zone (SDZ) on ED 6.5 (Fig. 2, G and H). This
pattern of proliferation in the decidua is
characteristic of pregnancy in intact animals
(37). Double staining with PECAM and
BrdU identifies proliferating BEC among the
population of the dividing cells on ED 3.5,
5.5, and 6.5 (Fig. 2, K–P).
To demonstrate that PROPmice undergo
a “typical” decidual reaction, stromal differentiation was as-
sessed by alkaline phosphatase staining on ED 6.5 (supplemental
Fig. 3). These data indicate that decidual vascular events, cellular
proliferation, and stromal differentiation in PROPmice are sim-
ilar to that of intact pregnant animals.
Expression of VEGFRs and VEGFR ligands in peri-
implantation uteri of PROPmice
VEGFRs are expressed in the uterus during the peri-im-
plantation period. However, each receptor has a unique pat-
tern of expression (Fig. 3). After implantation, VEGFR-1 and
VEGFR-3 are both expressed in the PDZ (Fig. 3, B–E and
L–O). Whereas the subset of cells expressing VEGFR-1 shows
a circular peri-embryonic staining pattern, staining for
VEGFR-3 is restricted to the mesometrial pole. VEGFR-2 ex-
pression is prominent in the PDZ on ED 5.5, but on ED 6.5
FIG. 2. Uterine angiogenesis and cellular proliferation during the peri-implantation period are dynamic
processes with reproducible patterns. A–E, BEC, detected by PECAM expression, are shown as brown
staining in representative cross-sections of pregnant uteri from PROPmice. BEC are prominent in both the
endometrium (em) and myometrium (myo) on ED 3.5 (A). Uterine vascular density peaks between ED 6.5
and 7.5 (C and D) and declines to reach its nadir on ED 8.5 (E). The reduction in uterine vascular density is
most pronounced at the site of placenta formation (arrow in E). F–J, BrDU expression is shown as brown
staining in representative cross-sections of pregnant uteri from PROPmice. On ED 5.5 (panel G), cellular
proliferation, indicated as BrDU-positive cells, occurs in the area around the embryo, the PDZ. In contrast,
on ED 6.5 (H), cellular proliferation is prominent in the SDZ. Cellular proliferation peaks on ED 5.5 (G) and
declines on ED 6.5 (H) and 7.5 (I) to reach its nadir on ED 8.5 (arrow in J). The reduction in cellular
proliferation is most pronounced at sites of placenta (arrow in J). Immunofluorescent double staining of
uterine cross-sections for BEC (PECAM, green) and proliferating cells (BrDU, red) demonstrates that many
of the proliferating cells in the decidua are BEC (K–P). Proliferating BEC are concentrated in the PDZ on ED
5.5 (L) and in the SDZ on ED 6.5 (M). Yellow staining cells, highlighted by insets (N–P), represent active
decidual angiogenesis. Q, Quantification of peri-implantation blood vessels and cellular proliferation. All
experiments were performed a minimum of three times. Scale bars, 200 m (for A, B, F, G, and K–M) and
100 m (for C–E and H–J). E, Embryo location.
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staining for VEGFR-2 is more prominent in the SDZ (Fig. 3,
F and G). This pattern of expression is similar to the pattern
for cellular proliferation, suggesting vascular proliferation
(Fig. 2, G and H). Although both VEGFR-2 and VEGFR-3 are
expressed in the mesometrial pole on ED 7.5, the subset of cells
expressing these receptors differs (Fig. 3, D and N). Immunofluo-
rescent double labeling demonstrated that VEGFRs are coex-
pressed with PECAM (Fig. 3, E, J, and O), and VEGFR-1 and
VEGFR-3 are coexpressed with VEGFR-2 (supplemental Fig. 4).
RT-PCR was used to detect mRNA expression of VEGFR ligands,
VEGFA, VEGFC, and VEGFD, on ED 6.5 (supplemental Fig. 5).
Effect of VEGFR-2 (DC101), VEGFR-3 (mF4-31C1), or
VEGFR-1 (MF-1) neutralization on blood vessel
development, cellular proliferation and apoptosis
After DC101, mF4-31C1, and MF-1 treatment, the per-
centages of the decidua occupied by blood vessels were 9.1 
1.0%, 13.1  0.7%, and 17.2  1.1%, respectively, whereas
they were 20.8  0.9% in the controls (Fig. 4G). Neutraliza-
tion of VEGFR-2 and VEGFR-3, but not VEGFR-1 signifi-
cantly reduced the percentage of the decidua occupied by
blood vessels (P  0.05). To determine whether blocking
VEGFR-2 and VEGFR-3 would have an additive effect, we
administered a combination DC101/mF4-31C1 treatment.
Compared with DC101 alone, there was no statistically sig-
nificant difference in the percentage of the deciduae occupied
by blood vessels (7.2  0.9%) after DC101/mF4-31C1 treat-
ment (Fig. 4G).
Histological analyses of uterine cross-sections demonstrated
that treatment with DC101 significantly reduced decidual
vasculature and stromal cell differentiation (controls 43.2 
4.7%; DC101 22.9  2.4%) (supplemental Fig. 3) and ar-
rested embryonic development. Embryonic structures were
absent after DC101 treatment. In contrast, a normal-appear-
ing, intact embryo was detected after mF4-31C1 treatment
(Fig. 4). The attached embryo was noted on ED 5.5 and 6.5
after DC101 treatment (supplemental Fig. 6). Thus, we con-
cluded that the reduction in decidual vasculature was not due
to failed implantation.
To investigate the mechanism(s) responsible for the reduction
in decidual blood vessels, cellular proliferation was assessed on
ED 5.5 and 7.5, and apoptosis was assessed on ED 7.5. Data for
ED 5.5, the time of peak proliferation in untreated animals, and
ED 7.5 show similar trends. Neutralization of VEGFR-2 or
VEGFR-3 significantly reduced cellular proliferation in the de-
cidua (P  0.05) (Fig. 4G). In control animals, 43.6  0.6% of
the decidual cells were proliferating. The percentages of prolif-
erating cells after DC101, mF4-31C1, MF1, and DC101/mF4-
FIG. 3. VEGFR-1, -2, and -3 have unique expression patterns in the peri-implantation uterus and distinct populations of newly formed peri-implantation BEC express
VEGFR-1, -2, and -3. On ED 3.5, VEGFR-2 (F) expression is easily detected throughout the endometrium and myometrium, whereas VEGFR-1 (A) and VEGFR-3 (K)
expression is scant. VEGFR-2 is expressed on cells in both the PDZ and SDZ. On ED 5.5, VEGFR-2 (G) expression is most intense directly adjacent to the embryo. On ED 6.5,
VEGFR-2 (H) expression is primarily in the SDZ with weaker expression in the PDZ. VEGFR-1 (B–D) and VEGFR-3 (K–N) are expressed in the PDZ directly surrounding the
implanted embryo. The expression patterns of VEGFR-1 and VEGFR-3 on ED 6.5 (C, H) and ED 7.5 (D, M) differ. On ED 7.5, there is prominent expression of both VEGFR-2 (m; I) and
VEGFR-3 (m; N) in the mesometrial pole; however, the patterns of expression differ. Immunofluorescent double staining for PECAM (green) and VEGFR-2 (red) shows
significant coexpression in the SDZ on ED 6.5 (J). Yellow staining cells in the PDZ on ED 6.5 (E), represent the subset of BEC (green) expressing VEGFR-1 (red). Yellow
staining cells in the PDZ (O) represent the subset of BEC (green) expressing VEGFR-3 (red). All experiments were performed a minimum of three times. Scale bars, 200
m (A, B, E–G, J–L, O) and 100 m (C, D, H, I, M, N).
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31C1 combination treatment were 25.7  0.9, 37.5  1.2,
35.4  0.01, and 27.7  1.6%, respectively. The reduction in
cellular proliferation with DC101 or DC101/mF4-31C1 com-
bination therapy was significantly greater than with mF4-31C1
treatment (P  0.05). Representative uterine cross-sections on
ED 5.5 for DC101 and mF4-31C1 are presented (Fig. 4, E and
F). After treatment with DC101 or mF4-31C1, the percentages
of proliferating cells and proliferating BEC (Fig. 4, E and F) were
reduced. On ED 7.5, 0.12% of decidual cells were apoptotic in
the controls. None of the treatments significantly increased the
percentage of apoptotic cells (0.3%) when compared with con-
trols. We concluded that a reduction in cellular proliferation, not
an increase in apoptosis, is the primary mechanism by which
VEGFR neutralization leads to decreased decidual vasculature.
Effect of VEGFR-2 (DC101), VEGFR-3 (mF4-31C1), or
VEGFR-1 (MF-1) neutralization on embryonic
development
Administration of DC101, but not mF4-31C1 or MF-1, to
PROPmice on ED 3.75 disrupted pregnancy development eval-
uated on ED 10.5 (Fig. 5). Each single ip in-
jection of DC101, mF4-31C1, or MF-1 re-
sulted in a uterus with a normal number of
implantation sites. The gross and micro-
scopic appearances of uteri from mice treated
with mF4-31C1 or MF-1 were indistinguish-
able from those of the controls (Fig. 5). Uteri
from DC101-treated mice appeared dark,
possibly consistent with hemorrhaging in the
implantation sites. H&E staining of uterine
cross-sections confirmed abnormal embry-
onic development, because no normal em-
bryonic structures were detected (Fig. 5G).
Effects of DC101 on embryonic develop-
ment were seen as early as ED 6.5 (supple-
mental Fig. 6).
In contrast, neutralization of VEGFR-2
starting on ED 6.5 did not affect pregnancy
development on ED 10.5. Statistically iden-
tical numbers of embryos (controls 10.7 
1.2; DC101 13.7  0.9) and embryo weights
(controls 0.138  0.01 g; DC101 0.110 
0.02 g) were noted. Thus, the timing of the
antibody injections is critical (16).
Neutralization of VEGFR-2 reduces
uterine vasculature in a model of
artificial decidualization
An intraluminal injection of 10 l sesame
oil was used to induce artificial decidualiza-
tion in pseudopregnant PROPmice. Decidual
morphology and peri-implantation blood
vessel development were evaluated on ED
7.5 (Fig. 6, A and B). DC101/mF4-31C1
combination therapy reduced decidual vas-
culature and led to abnormal-appearing,
small deciduae (Fig. 6, D–F). These results
are similar to those observed after DC101 treatment in PROP-
mice (Fig. 4B). This finding indicates that the VEGF/VEGFR-2
pathway might have a regulatory role in angiogenesis during
artificial decidualization.
Discussion
Reduction of angiogenesis in the uterine decidua during the early
postimplantation period with the anti-VEGFR-2 blocking anti-
body, DC101, decreases decidual vascular density and stromal
cell differentiation. These changes disrupt embryonic develop-
ment. Although blockage of the VEGFC/VEGFR-3 pathway re-
duces decidual vasculature and proliferation, the progression of
pregnancy is not precluded. In contrast, the administration of an
anti-VEGFR-1 antibody has no affect on peri-implantation an-
giogenesis, vascular density, or pregnancy development. Thus,
the VEGF/VEGFR-2-signaling pathway regulates the formation
of new vasculature in the peri-implantation period, which is es-
sential for the creation of a functional decidua.
FIG. 4. Inhibition of VEGFR-2 during the peri-implantation period disrupts embryonic development
because of a reduction in peri-implantation uterine blood vessels and cellular proliferation. Mice treated
with the DC101 or mF4-31C1 have significantly reduced uterine vascular density (B, C, G) and cellular
proliferation (E–G) compared with controls (A and D; n  5 per group). Uterine vascular density and
cellular proliferation after MF-1 treatment were statistically identical to untreated PROPmice controls (G).
Note the decrease in cellular proliferation (BrDU, red) and BEC proliferation [BrDU (red)  PECAM (green)]
in the decidua of DC101- (E) and mF4-31C1- (F) treated mice on ED 5.5. *, P  0.05 compared with
PROPmice controls. ˆ, P  0.05 compared with DC101 or DC101/mF4-31C1 treatment. Scale bars, 100
m (A–C) and 200 m (D–F).
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VEGFA- and VEGFC/VEGFD-dependent signaling path-
ways are essential to ovarian function (7, 16, 24) and embryonic
development (31–33, 35). Both the embryo (18) and corpus lu-
teum (38) participate in the process of decidualization. To eval-
uate whether VEGFR-dependent signaling pathways are active
during decidual angiogenesis, it was important to ensure that
potential effects of VEGFR-blocking antibodies were restricted
to the uterus. To achieve this, we used PROPmice with time-
specific, systemic administration of VEGFR-blocking antibodies
(16). Antibodies were administered on ED 3.75, 1 h after ovari-
ectomy and after the attachment reaction and decidualization
had been initiated (5). We avoided the effects of the antibodies on
embryonic development by injecting the VEGFR-blocking anti-
bodies 3 days before VEGFR expression was initiated in the
embryo (31). Validity of such an experimental approach comes
from gene knockout models, which demonstrate that absence of
either VEGFR-1 (31), -2 (35), or -3 (32) does not interfere with
implantation or early embryonic development. Because the bi-
ological action of a single antibody injection generally lasts for
about 3 days (28), it is possible that after administration on ED
3.75, biologically relevant antibody concentrations are present
on ED 6.5, the point when the VEGFRs start to be expressed in
the embryo. However, blocking antibodies did not penetrate the
embryo (16). To further exclude such a possibility we injected
VEGFR-blocking antibodies on ED 6.5 and 9.5. In both cases,
embryonic development progressed normally when pregnancy
was evaluated on ED 10.5. In addition, after systemic adminis-
tration of DC101 or mF4-31C1 on ED 9.5, neither was detected
by immunohistochemical analysis in the ED-10.5 embryos.
Thus, the antibodies did not significantly penetrate the embryo
FIG. 5. Inhibition of VEGFR-2 but not VEGFR-1 or VEGFR-3 during the peri-implantation period disrupts pregnancy development evaluated on ED 10.5. A–D, Intact
uteri containing embryos on ED 10.5. Uteri from isotype-matched, IgG-injected PROPmice controls (A), anti-VEGFR-1 (MF-1)-treated mice (B), anti-VEGFR-2 (DC101)-
treated mice (C), and anti-VEGFR-3 (mF4-31C1)-treated mice (D) contain similar numbers of implantation sites (I). The gross appearance of DC101-treated mice (C)
reveals hemorrhage in the implantation sites. E–H, Cross-sections of uteri on ED 10.5 from PROPmice controls (E), MF-1- (F), DC101- (G), and mF4-31C1- (H) treated
mice. Note the empty lumen in DC101-treated mice (G; arrow). The number of implantation sites, the number of embryos, and the embryo weights were statistically
identical (P  0.05) in all groups except DC101 treatment (I and J; n  5 per group). Scale bars, 5 mm (A–D) and 100 m (E–H).
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to block vascular development directly. In summary, three fac-
tors permitted examination of peri-implantation decidual an-
giogenesis: the combination of PROPmice, the timing of the
VEGFR-blocking antibody injection, and the lack of antibody
penetration to the embryo.
During implantation, a profound P4-dependent increase in
cellular proliferation occurs in the stromal tissue surrounding the
avascular embryo (38). In our model, cellular proliferation on
ED 5.5 occurs throughout the developing decidua including the
PDZ adjacent to the embryo, whereas on ED 6.5 proliferation is
more profound in the SDZ, similar to previously published re-
ports (37). Many of the dividing cells identified in the decidua are
proliferating EC as has been reported for pregnancies with intact
ovaries (4). The identification of proliferating EC in the antime-
sometrial area indicates that angiogenesis is not restricted to the
mesometrial region as has been previously speculated (3, 39). An-
giogenesisoccurs inallareassurroundingtheembryoduringuterine
decidualization. As a result of this process, the embryo is tempo-
rarily surrounded by a dense vascular network on ED 6.5 and 7.5.
As noted in intact pregnancies (40), EC are evenly distributed in the
PDZ and SDZ. Based on lack of expression of smooth muscle actin
(41), this newly formed peri-embryonic vasculature consists of im-
mature vessels of the capillary type (supplemental Fig. 7). In sum-
mary, thedecidualvasculareventsobservedinourmodelaresimilar
to events occurring in intact, pregnant animals.
We demonstrate specific expression patterns for VEGFRs in
the newly formed decidual vasculature. BEC in PDZ and SDZ
differ in the amount of VEGFR-2 expressed. VEGFR-2 colocal-
izes with PECAM BEC in the SDZ, whereas weaker VEGFR-2
staining of PECAM BEC was observed in the PDZ. Although
in situ hybridization revealed similar findings in the SDZ (3), the
finding of PECAM BEC in the PDZ was surprising because it
was previously reported that this zone is devoid of blood vessels
(36). This discrepancy might be attributable to differences in the
sensitivity of the methodologies used to detect blood
vessels: immunohistochemistry (Douglas N. C.,
H. Tang, and R. C. Zimmermann, unpublished
data) vs. LacZ staining in Flk-1lacZ mice (36) and in
situ hybridization (3, 36). The profound reduction in
vascular formation that resulted from VEGFR-2
neutralization was not unexpected because nearly
all newly formed decidual vasculature expresses
VEGFR-2.
Double staining with antibodies against VEGFR-3
and the EC marker PECAM reveals consistent co-
expression, whereas coexpression of LYVE-1, a
lymphatic marker, and VEGFR-3 is rare (our un-
published observations). In addition, VEGFR-3
consistently coexpresses with VEGFR-2. These ob-
servations suggest that, in the murine decidua, the
VEGFR-3-expressing tubular structures noted in the
PDZ are simple blood vessels, not lymphatics. It has
been recently demonstrated that VEGFR-3 blood
vessels are common in ovarian follicles of superovu-
lated mice (24), tumor angiogenesis (23), and
sprouting angiogenesis in the retina (24). The find-
ing that inhibition of VEGFR-3 only partially
blocked angiogenesis is consistent with the localization of this
receptor to vasculature in the PDZ. It is possible that VEGFR-2
activation compensated for the inactivation of VEGFR-3 on
some of the vessels that express both receptors. The effects of
VEGFR-3 neutralization demonstrated that the embryo can tol-
erate, within limits, disturbances of vascular formation in uterine
deciduae. In contrast, the neutralization of VEGFR-1 had no effect
on decidual angiogenesis. VEGFR-1 acts primarily through re-
cruitment of bone marrow-derived endothelial and hematopoi-
etic cells to areas of active angiogenesis (27, 30, 42). It is unclear
whether VEGFR-1 has a specific role during decidual angiogen-
esis or if receptor expression merely points to the origin of these
EC. mRNA expression of the VEGFR ligands supports our find-
ings that VEGFR-2- and VEGFR-3-signaling pathways are ac-
tive during peri-implantation uterine angiogenesis (3).
Significant time-limited proliferation of epithelial or epithe-
lial-like cells and EC occurs in maternal tissue under physiolog-
ical conditions such as formation of corpora lutea and formation
of uterine deciduae in early pregnancy. Regulation of luteal an-
giogenesis involves glycoprotein hormones such as LH, which
originate in the pituitary gland and stimulate VEGF production
in luteinized granulosa cells (7). In contrast, steroid hormones
like P4 originate in the ovary and are involved in the regulation
of decidual angiogenesis. Because expression of P4 receptors in
uterine EC is very low, and in vitro stimulation of such cells
results in minimal to no proliferation (43), it is likely that P4-
dependent angiogenesis works by indirect means through P4
receptors active in fibroblasts or decidual cells (10, 38, 44). In the
presence of comparable serum P4 levels, uterine EC proliferation
after implantation is significantly higher than EC proliferation
before implantation (4). This observation makes it likely that
implantation of the embryo provides a stimulus that significantly
enhances angiogenesis through formation of the decidua. Be-
cause early pregnancy development proceeds normally in
FIG. 6. Inhibition of VEGFR-2 and VEGFR-3 reduces uterine vasculature induced by artificial
decidualization. Representative cross-sections of uteri from pseudopregnant PROPmice on d 6.5
of pseudopregnancy were stained with H&E (A and D) and PECAM (B and C). When compared
with pseudopregnant control mice (B and C), the uterine vasculature was reduced after DC101/
mF4-31C1 treatment (E and F). Insets (C and F) correspond to boxes in panels B and E and
highlight differences in vascular density. Each experiment was performed three times. Scale bars,
100 m (A–E) and 100 mm (C and F).
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VEGFR knockout mice (33), it is unlikely that the nature of the
stimulus is a specific proangiogenic factor produced by the em-
bryo. In this context, it is important to recall that mechanical
stimulation (e.g. sesame oil) of hormonally primed uteri results
in uterine decidualization and blood vessel development in the
absence of an embryo (18, 45). Artificial decidualization induces
VEGF and VEGFR expression (3). Blocking VEGFR-2 and
VEGFR-3 provides the most marked reduction in vasculature
(see Fig. 4 and Ref. 24). To initiate an investigation of the role of
VEGFRs in artificial decidualization, we administered the
DC101/mF4-31C1 combination to pseudopregnant mice. Our
results indicate that neutralization of VEGFR-2 and VEGFR-3
pathways inhibits angiogenesis under such conditions. Thus, me-
chanical stimuli can substitute for an embryo in the initiation of
VEGFR-mediated decidual angiogenesis. Based on these obser-
vations, it is clear that P4 is a prerequisite for peri-implantation
angiogenesis, but another natural or artificial stimulus is needed
to actually induce decidual angiogenesis that involves the
VEGFR family. As a result of these stimuli, decidual cells become
a major source of stromal VEGF production, which explains the
robust expression of this compound in early pregnancy (3). Be-
cause implantation and artificial decidualization are similar to
inflammatory processes, we speculate that resident uterine white
blood cells like neutrophils and macrophages, some of which are
likely to be derived from bone marrow, might become activated
through such decidualization stimuli and serve as a second
source of VEGF (46–49). Indeed, uterine dendritic cells are re-
quired for early vascular events associated with implantation
(50), and bone marrow-derived white blood cells are critical for
angiogenesis in cancer (42). Therefore, inhibition of VEGFR-2
function might not only have blocked local sprouting of blood
vessels but could have also interfered with the recruitment and
function of bone marrow-derived VEGFR-2-positive cells.
Our observations in the mouse are clinically significant be-
cause they elucidate the involvement of VEGF-dependent angio-
genesis in the uterus during early pregnancy. Our findings sug-
gest that abnormal peri-implantation angiogenesis due to
dysfunction of the VEGF/VEGFR-2 signaling pathway could be
a cause of early miscarriage (21, 51). Therefore, one should use
agents like cabergoline (52), which could disrupt decidual vas-
cularization when used to treat ovarian hyperstimulation syn-
drome, or cyclooxygenase-2 inhibitors (36) used to treat pelvic
pain with caution during early pregnancy. On the other hand,
our findings might explain why cyclooxygenase inhibitors are
helpful in treating dysfunctional uterine bleeding (53, 54).
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